• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Novel diagnostic examination and treatment of radiation necrosis based on molecular pathological mechanism

Research Project

Project/Area Number 17K10911
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Research Field Neurosurgery
Research InstitutionOsaka Medical College

Principal Investigator

Furuse Motomasa  大阪医科大学, 医学部, 准教授 (70340560)

Co-Investigator(Kenkyū-buntansha) 川端 信司  大阪医科大学, 医学部, 准教授 (20340549)
野々口 直助  大阪医科大学, 医学部, 講師 (70388263)
Project Period (FY) 2017-04-01 – 2020-03-31
Project Status Completed (Fiscal Year 2019)
Budget Amount *help
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2019: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2018: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Keywords放射線壊死 / 血管新生 / 炎症 / 放射線画像診断 / ベバシズマブ / HIF-1 / VEGF / 放射線学的診断 / bevacizumab / brain tumor / radiation necrosis / radiological diagnosis / 癌 / 脳腫瘍 / X線
Outline of Final Research Achievements

Radiation necrosis was made in rat by linear accelerator and was more obvious 7 months after irradiation. In microarray analysis for mRNA and miRNA, differential expression was frequently observed in gene pathway for inflammatory and immune system. Systematic review of radiological diagnosis for radiation necrosis was performed to elucidate the diagnostic accuracy of radiological examinations to distinguish radiation necrosis and tumor progression. The diagnostic odds ratio of radiological examinations were different between glioma and metastatic brain tumor. Combined multiparametric imaging including lesional metabolism and blood flow could enhance diagnostic accuracy, compared with a single imaging study. In treatment of radiation necrosis, three cycles of 5mg/kg bevacizumab could have a treatment effects of reducing perilesional edema.

Academic Significance and Societal Importance of the Research Achievements

化学療法、分子標的治療、免疫療法および新規放射線治療などがん治療の研究が進む一方で、生じうる合併症を克服する取り組みも重要である。脳腫瘍治療において放射線治療は不可欠であり、その有害事象の改善なくして放射線治療の進歩はないと考える。放射線壊死の予防、診断、治療を可能とするためにはその病態メカニズムを明らかにすることが必要である。放射線壊死の動物モデルの作成は困難であり、多くの施設で試みられているが確実な方法がない。また診断方法においてもどの画像診断が有用かも十分明らかになっておらず、治療においてはエビデンスのある治療はない。本研究の成果はこれらの問題点に対して解決の一助となると考える。

Report

(4 results)
  • 2019 Annual Research Report   Final Research Report ( PDF )
  • 2018 Research-status Report
  • 2017 Research-status Report
  • Research Products

    (9 results)

All 2019 2018 2017

All Journal Article (3 results) (of which Peer Reviewed: 3 results,  Open Access: 3 results) Presentation (6 results) (of which Int'l Joint Research: 1 results)

  • [Journal Article] Radiological diagnosis of brain radiation necrosis after cranial irradiation for brain tumor: a systematic review2019

    • Author(s)
      Furuse Motomasa、Nonoguchi Naosuke、Yamada Kei、Shiga Tohru、Combes Jean-Damien、Ikeda Naokado、Kawabata Shinji、Kuroiwa Toshihiko、Miyatake Shin-Ichi
    • Journal Title

      Radiation Oncology

      Volume: 14 Issue: 1 Pages: 28-28

    • DOI

      10.1186/s13014-019-1228-x

    • Related Report
      2018 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Radiation necrosis after cranial irradiation for brain tumors2018

    • Author(s)
      古瀬 元雅、野々口 直助、池田 直廉、川端 信司、宮武 伸一、黒岩 敏彦
    • Journal Title

      Progress in Neuro-Oncology

      Volume: 25 Issue: 1 Pages: 23-32

    • DOI

      10.11452/neurooncology.25.1_23

    • NAID

      130006728649

    • ISSN
      1880-0742, 2187-0551
    • Year and Date
      2018-04-28
    • Related Report
      2017 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Boron Neutron Capture Therapy Combined with Early Successive Bevacizumab Treatments for Recurrent Malignant Gliomas ? A Pilot Study2018

    • Author(s)
      SHIBA Hiroyuki、TAKEUCHI Koji、HIRAMATSU Ryo、FURUSE Motomasa、NONOGUCHI Naosuke、KAWABATA Shinji、KUROIWA Toshihiko、KONDO Natsuko、SAKURAI Yoshinori、SUZUKI Minoru、ONO Koji、OUE Shiro、ISHIKAWA Eiichi、MICHIUE Hiroyuki、MIYATAKE Shin-Ichi
    • Journal Title

      Neurologia medico-chirurgica

      Volume: 58 Issue: 12 Pages: 487-494

    • DOI

      10.2176/nmc.oa.2018-0111

    • NAID

      130007531206

    • Related Report
      2018 Research-status Report
    • Peer Reviewed / Open Access
  • [Presentation] グリオーマの放射線壊死鑑別に有用な画像診断 -systematic reviewのサブ解析より-2019

    • Author(s)
      古瀬 元雅、野々口 直助、山田 惠、志賀 哲、Jean-Damien Combes,池田 直廉、川端 信司、鰐渕 昌彦、黒岩 敏彦、宮武 伸一
    • Organizer
      第37回日本脳腫瘍学会学術集会
    • Related Report
      2019 Annual Research Report
  • [Presentation] Bevacizumab holidayは可能か? 初発膠芽腫に対するbevacizumab治療2018

    • Author(s)
      古瀬 元雅、川端 信司、池田 直廉、野々口 直助、宮武 伸一、黒岩 敏彦
    • Organizer
      日本脳神経外科学会 第77回学術総会
    • Related Report
      2018 Research-status Report
  • [Presentation] Bevacizumab holidayは可能か? 初発膠芽腫に対するbevacizumab治療2018

    • Author(s)
      古瀬 元雅、川端 信司、池田 直廉、野々口 直助、黒岩 敏彦
    • Organizer
      第56回日本癌治療学会学術総会
    • Related Report
      2018 Research-status Report
  • [Presentation] 放射線壊死の診断 システマティックレビュー2017

    • Author(s)
      古瀬 元雅、野々口 直助、山田 惠、志賀 哲、池田 直廉、川端 信司、黒岩 敏彦、宮武 伸一
    • Organizer
      日本脳神経外科学会 第76回学術総会
    • Related Report
      2017 Research-status Report
  • [Presentation] Impact of bevacizumab in patients with recurrent glioblastoma and poor performance status.2017

    • Author(s)
      Motomasa Furuse, Shinji Kawabata, Naokado Ikeda, Naosuke Nonoguchi, Yoji Tamura, Yoshinaga Kajimoto, Shin-Ichi Miyatake, Toshihiko Kuroiwa
    • Organizer
      22nd Annual Meeting of the Society for Neuro-Oncology
    • Related Report
      2017 Research-status Report
    • Int'l Joint Research
  • [Presentation] ベバシズマブは放射線脳壊死に薬事承認されるか?  AVAnecro進捗状況の報告2017

    • Author(s)
      古瀬 元雅、野々口 直助、川端 信司、黒岩 敏彦、宮武 伸一
    • Organizer
      第35回日本脳腫瘍学会学術集会
    • Related Report
      2017 Research-status Report

URL: 

Published: 2017-04-28   Modified: 2021-02-19  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi